{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:02:21Z","timestamp":1791414141574,"version":"4.3.3"},"reference-count":22,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:00:00Z","timestamp":1631836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:00:00Z","timestamp":1631836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2021,9,17]]},"abstract":"<jats:p>\n            The\n            <jats:italic>in vitro<\/jats:italic>\n            activity and\n            <jats:italic>in vivo<\/jats:italic>\n            efficacy of delafloxacin were evaluated against the causative pathogen of melioidosis,\n            <jats:named-content content-type=\"genus-species\">Burkholderia pseudomallei<\/jats:named-content>\n            . Delafloxacin MICs were determined by broth microdilution according to CLSI guidelines for 30 isolates of\n            <jats:named-content content-type=\"genus-species\">B. pseudomallei<\/jats:named-content>\n            .\n          <\/jats:p>","DOI":"10.1128\/aac.00736-21","type":"journal-article","created":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T20:34:55Z","timestamp":1627936495000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy of Delafloxacin against the Biothreat Pathogen Burkholderia pseudomallei"],"prefix":"10.1128","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1702-9072","authenticated-orcid":true,"given":"Sandra","family":"McCurdy","sequence":"first","affiliation":[{"name":"Melinta Therapeutics, Morristown, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Duffy","sequence":"additional","affiliation":[{"name":"Melinta Therapeutics, Morristown, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hickman","sequence":"additional","affiliation":[{"name":"Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), Joint Product Manager CBRN Medical, Frederick, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Halasohoris","sequence":"additional","affiliation":[{"name":"U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Frederick, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Zumbrun","sequence":"additional","affiliation":[{"name":"U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), Frederick, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00006-19"},{"key":"e_1_3_2_3_2","unstructured":"CDC. 2021. Melioidosis. https:\/\/www.cdc.gov\/melioidosis\/index.html."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.107"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.31128\/AJGP-04-18-4558"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.01.005"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.1998.tb00692.x"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0035-9203(97)90044-4"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00082-17"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01201-10"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.01.094"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/tra.12613"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00772-17"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy220"},{"key":"e_1_3_2_15_2","unstructured":"Melinta Therapeutics. 2017. Delafloxacin USPI. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208610s000 208611s000lbl.pdf."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm527"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(89)90768-x"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1086\/338723"},{"key":"e_1_3_2_19_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","author":"Clinical and Laboratory Standards Institute","year":"2012","unstructured":"Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"9"},{"key":"e_1_3_2_20_2","volume-title":"Performance standards for antimicrobial susceptibility testing; twenty-second informational supplement.","author":"Clinical and Laboratory Standards Institute","year":"2012","unstructured":"Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing; twenty-second informational supplement. CLSI Document M100-S22. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-8502(73)90006-2"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2003.07.001"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplegacy.1947.150.1.70"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00736-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00736-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:30:09Z","timestamp":1645486209000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00736-21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,17]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,9,17]]}},"alternative-id":["10.1128\/AAC.00736-21"],"URL":"https:\/\/doi.org\/10.1128\/aac.00736-21","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,17]]},"assertion":[{"value":"2021-04-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00736-21"}}